CY1109097T1 - Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας - Google Patents

Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας

Info

Publication number
CY1109097T1
CY1109097T1 CY20091100557T CY091100557T CY1109097T1 CY 1109097 T1 CY1109097 T1 CY 1109097T1 CY 20091100557 T CY20091100557 T CY 20091100557T CY 091100557 T CY091100557 T CY 091100557T CY 1109097 T1 CY1109097 T1 CY 1109097T1
Authority
CY
Cyprus
Prior art keywords
cadherin
human
canadin
competitors
antibodies
Prior art date
Application number
CY20091100557T
Other languages
Greek (el)
English (en)
Inventor
Fang Liao
Daniel J Hicklin
Peter Bohlen
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of CY1109097T1 publication Critical patent/CY1109097T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20091100557T 2000-03-31 2009-05-25 Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας CY1109097T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31
EP01922997A EP1268799B1 (en) 2000-03-31 2001-03-30 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability

Publications (1)

Publication Number Publication Date
CY1109097T1 true CY1109097T1 (el) 2014-07-02

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100557T CY1109097T1 (el) 2000-03-31 2009-05-25 Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας

Country Status (12)

Country Link
US (4) US7371574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1268799B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003529370A (cg-RX-API-DMAC7.html)
AT (1) ATE425255T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001249737A1 (cg-RX-API-DMAC7.html)
CA (1) CA2404576A1 (cg-RX-API-DMAC7.html)
CY (1) CY1109097T1 (cg-RX-API-DMAC7.html)
DE (1) DE60137915D1 (cg-RX-API-DMAC7.html)
DK (1) DK1268799T3 (cg-RX-API-DMAC7.html)
ES (1) ES2323938T3 (cg-RX-API-DMAC7.html)
PT (1) PT1268799E (cg-RX-API-DMAC7.html)
WO (1) WO2001075109A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
CA2506037A1 (en) 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE69332948T2 (de) * 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
CA2111573C (en) * 1992-04-17 2002-11-26 Shintaro Suzuki Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
US7371574B2 (en) 2008-05-13
JP2003529370A (ja) 2003-10-07
ATE425255T1 (de) 2009-03-15
EP1268799B1 (en) 2009-03-11
EP1268799A2 (en) 2003-01-02
DK1268799T3 (da) 2009-07-06
AU2001249737A1 (en) 2001-10-15
ES2323938T3 (es) 2009-07-28
US20080317750A1 (en) 2008-12-25
CA2404576A1 (en) 2001-10-11
PT1268799E (pt) 2009-05-11
US20020160003A1 (en) 2002-10-31
WO2001075109A2 (en) 2001-10-11
DE60137915D1 (de) 2009-04-23
WO2001075109A3 (en) 2002-05-16
US20080311121A1 (en) 2008-12-18
US20090060909A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
BR112022013756A2 (pt) Anticorpos anti-trem2 e métodos de uso dos mesmos
ATE121130T1 (de) Monoklonaler antikörper, spezifisch gegen den funktionellen adhäsionsbereich des oberflächenproteins einer phagocyten-zelle.
DE69230545D1 (de) Antikörperderivate
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
FI854187A0 (fi) Immunoanalyser foer denaturerade proteinanalyser, saerskilt hb alc, samt antikroppar anvaendbara i dessa.
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
EP1285577A4 (en) CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
EP4112723A4 (en) KPC-TYPE CARBAPENEMASE RESISTANT HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY (MAB) AND USE THEREOF
IT1257893B (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
DK0457804T3 (da) M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
DE68921360D1 (de) Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus.
DE69529744D1 (de) Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen
EP0585364A4 (en) THE ANTIQUE CTAA 81AV78 RECOGNIZED BY THE MONOCLONAL HUMAN ANTIBODY 81AV78.
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
EP1359161A3 (en) Monoclonal antibody specific to tartrate-resistant acid phosphatase 5b and use thereof
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
DK414386D0 (da) Monoklonalt antistof, cellelinje til fremstilling deraf og antistoffets anvendelse
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
Young Monoclonal antibodies directed against the flagellar basal apparatus of Chlamydomonas reinhardtii
FI881631A7 (fi) Monoklonaalinen anti-R-sitojavasta-aine, sen valmistus ja käyttö.